Math Biology srl

Develops AI-native DMA® non-invasive screening of bioelectrical signals for metabolic digital twins in health.

Website: https://mathbiology.tech

Cover Block

PUBLIC

Attribute Value
Name Math Biology srl
Tagline Develops AI-native DMA® non-invasive screening of bioelectrical signals for metabolic digital twins in health. [Perplexity Sonar Pro Brief, current]
Founded 2020
Stage Pre-Seed
Business Model B2B
Industry Healthtech
Geography Western Europe (Italy)
Growth Profile Venture Scale
Founding Team Co-Founders (2)
Total Disclosed Funding $1.5M (estimated) [SignalBase]

Links

PUBLIC

Executive Summary

PUBLIC Math Biology srl is an Italian healthtech startup developing a non-invasive, AI-powered metabolic screening platform, a proposition that warrants investor attention for its attempt to digitize a foundational physiological process ahead of clinical symptoms [Perplexity Sonar Pro Brief, current]. Founded in 2020, the company's core technology, DMA® (Deep Metabolic-Processes Assessment), analyzes bioelectrical signals from 61 body points to create a digital twin of a patient's metabolism across 38 brain and organ districts [Perplexity Sonar Pro Brief, current]. The founding team pairs Giuseppe Sgro, who brings over three decades of field experience tied to the patented DMA® biosensor, with Raffaele Maccioni, a mathematical optimization expert and Franz Edelman award winner [Perplexity Sonar Pro Brief, current]. While the company claims a $1.5 million funding round, this figure is not corroborated by major financial databases, and no lead investors are named [SignalBase]. Its business model targets a B2B ecosystem of clinics, pharmaceutical companies, and insurers, and it gained early validation through selection for the Innovit acceleration program in May 2024 [Math Biology, May 2024]. Over the next 12-18 months, the critical milestones to watch are the translation of its academic patent into a commercially deployed product and the securing of verifiable pilot partnerships with healthcare institutions.

Data Accuracy: YELLOW -- Core product and team claims sourced from a single aggregated research brief; funding claim from an unverified press release.

Taxonomy Snapshot

Axis Classification
Stage Pre-Seed
Business Model B2B
Industry / Vertical Healthtech
Geography Western Europe
Growth Profile Venture Scale
Founding Team Co-Founders (2)

Company Overview

PUBLIC

Math Biology srl is an Italian health technology startup founded in 2020. The company's public narrative centers on developing a non-invasive diagnostic platform, but its corporate footprint is minimal. The founding story, as presented by the company, ties the venture to the scientific work of co-founder Giuseppe Sgro, who has over three decades of experience in the field and is credited with the underlying DMA® biosensor technology [Perplexity Sonar Pro Brief, current].

The company's key milestones follow a pattern typical of deep-tech academic spinouts. In April 2023, Math Biology secured a patent for its DMA® biosensor, a foundational piece of intellectual property for its screening platform [Perplexity Sonar Pro Brief, current]. A subsequent signal of external validation came in May 2024, when the company was selected as one of 15 startups for the Innovit acceleration program, which connects Italian startups to Silicon Valley networks [Math Biology, May 2024]. The company has also listed itself as an exhibitor at the BIO International Convention for 2026, indicating an intent to engage with the global biotech community [BIO International Convention].

Data Accuracy: YELLOW -- Key milestones (patent, accelerator selection) are cited from company sources; foundational details like headquarters location are not publicly confirmed.

Product and Technology

MIXED The company’s sole public asset is a patented biosensor and its associated software platform, DMA® (Deep Metabolic-Processes Assessment). The technology is designed to be a non-invasive screening tool, capturing bioelectrical signals from 61 points on the body during a 15 to 60 minute session [Perplexity Sonar Pro Brief, current]. These signals are processed by proprietary AI algorithms to generate what the company terms a metabolic digital twin, providing a functional assessment of metabolism across 38 brain regions, organs, and the central nervous system [Perplexity Sonar Pro Brief, current]. The company claims the system analyzes 7,000 biomarkers, aiming to detect metabolic dysregulation before clinical symptoms appear [Perplexity Sonar Pro Brief, current].

The hardware component, the DMA® biosensor, received a patent in April 2023 [Perplexity Sonar Pro Brief, current]. The company’s website and public materials position the system for early diagnosis, prevention, and treatment monitoring in chronic and oncological conditions, as well as for human performance enhancement [Perplexity Sonar Pro Brief, current]. Target users listed include healthcare professionals, clinics, and research institutions [Perplexity Sonar Pro Brief, current]. No specific details on the AI model architecture, data pipeline, or software stack are publicly available. The company has not released a public roadmap, and there is no evidence of a commercial deployment or named pilot customer.

Data Accuracy: YELLOW -- Core product description is consistent across the company's own materials and a third-party brief, but technical specifications and commercial readiness are unverified.

Market Research and Opportunity

PUBLIC The promise of non-invasive metabolic monitoring is emerging as a critical wedge in the shift from reactive to predictive healthcare, a transition driven by rising chronic disease burdens and the search for cost-effective, preventative tools.

Math Biology's technology targets a segment of the broader digital health and precision diagnostics market. The company's own materials frame the opportunity around early diagnosis and personalized medicine for chronic and oncological conditions, as well as human performance enhancement [Perplexity Sonar Pro Brief, current]. While no third-party TAM/SAM/SOM figures are cited for the company's specific niche, analogous markets provide context. The global digital twin in healthcare market was valued at approximately $1.6 billion in 2023 and is projected to grow at a compound annual rate of over 25% through the next decade, according to Grand View Research [analogous market, source]. Similarly, the broader metabolic testing market, which includes both invasive and non-invasive methods, is a multi-billion dollar space. The specific application of bioelectrical signal analysis for metabolic assessment, however, remains a nascent and less-defined sub-segment.

Key demand drivers for this category are well-documented across industry reports. The global rise in metabolic syndrome, diabetes, and cardiovascular diseases creates a pressing need for scalable screening tools. Concurrently, health systems and insurers are increasingly incentivized by value-based care models to invest in preventative solutions that can reduce long-term treatment costs. The expansion of remote patient monitoring and the integration of AI for data interpretation are enabling tailwinds. Math Biology's proposed wedge, analyzing 7,000 biomarkers from a non-invasive session, speaks directly to these drivers by aiming to detect metabolic shifts before symptomatic presentation [Perplexity Sonar Pro Brief, current].

The company's potential customers span several adjacent markets, each with its own dynamics. These include clinical diagnostics providers, pharmaceutical companies (for clinical trial patient stratification and treatment monitoring), corporate wellness and human performance programs, and private insurance providers seeking predictive risk models. Substitute technologies range from traditional, often invasive, lab-based metabolic panels (e.g., blood tests for HbA1c, lipid profiles) to other non-invasive or minimally invasive monitoring devices, such as continuous glucose monitors (CGMs) which, while focused on a single metric, have established significant commercial traction and patient adoption.

Regulatory pathways represent a significant macro force. In the European Union, where the company is based, DMA® would likely require certification as a Class II medical device under the EU Medical Device Regulation (MDR), a process that demands rigorous clinical validation, quality management systems, and post-market surveillance. Success in the U.S. market would necessitate FDA clearance, an even more resource-intensive undertaking. The absence of any cited regulatory milestones or partnerships with established medical device firms in the public record is a notable gap in the market execution narrative.

Market Segment Analogous Size / Growth (Source) Notes
Digital Twin in Healthcare ~$1.6B (2023), >25% CAGR (Grand View Research) Adjacent enabling technology market.
Metabolic Testing Multi-billion dollar global market Includes traditional lab tests and emerging monitoring tech.
Remote Patient Monitoring Rapid growth post-pandemic Broader category enabling non-invasive tools.

The available sizing data is illustrative of large, adjacent markets rather than a direct measure of Math Biology's addressable niche. The company's success hinges on carving out a defensible position within these expansive but competitive landscapes, a task that requires not only technical validation but also clear regulatory and commercial strategy.

Data Accuracy: YELLOW -- Market sizing is based on analogous, third-party industry reports for broader categories; specific TAM for the company's niche is not publicly quantified.

Competitive Landscape

MIXED

Math Biology positions itself as a pure-play AI-native metabolic assessment platform, a niche that currently lacks a direct, publicly traded competitor but exists within a dense ecosystem of adjacent diagnostic and digital health technologies.

Given the absence of named competitors in the structured facts, a direct comparison table is not rendered. The competitive analysis is presented as prose.

The competitive map for non-invasive metabolic assessment is fragmented across several distinct segments. On the incumbent side, established diagnostic giants like Roche and Abbott offer traditional blood-based biomarker tests (HbA1c, lipid panels) which are the clinical standard but are not real-time or holistic. A wave of challengers in the digital biomarker space includes companies like Levels, which uses continuous glucose monitors (CGMs) to provide metabolic insights directly to consumers, and January AI, which focuses on personalized nutrition predictions. These are closer in ambition but target a different data modality (biochemical vs. bioelectrical) and a primarily direct-to-consumer channel. In the adjacent research and clinical decision support segment, platforms like Tempus and SOPHiA GENETICS use multi-omics data and AI for oncology, representing a broader, more data-intensive, and often invasive approach to disease modeling that overlaps with Math Biology's stated interest in oncological conditions.

The subject's claimed defensible edge rests on two pillars: its proprietary DMA® biosensor, patented in April 2023, and the academic pedigree of its founding team in mathematical optimization [Perplexity Sonar Pro Brief, current]. The patent provides a temporary legal moat around the specific method of analyzing bioelectrical signals from 61 body points. The team's deep expertise in applied mathematics, highlighted by co-founder Raffaele Maccioni's Franz Edelman award, is a significant talent advantage for developing the core algorithms. However, these edges are perishable. The patent must withstand scrutiny and is likely narrow, protecting a specific implementation rather than the entire concept of bioelectrical metabolic analysis. The talent moat is vulnerable if well-funded incumbents or new entrants recruit similar expertise, a common occurrence in AI-driven healthtech.

Math Biology is most exposed in three areas. First, it lacks the commercial infrastructure and regulatory clearances that incumbents possess. Bringing a novel diagnostic device to market requires significant capital and time for clinical validation and FDA/CE marking, a process where it trails far behind established medical device companies. Second, it faces substitution risk from more mature, consumer-accessible technologies like CGMs, which are already FDA-cleared, covered by some insurers, and building large datasets. Third, its channel ownership is non-existent; the company's website speaks of seeking partnerships with clinics and pharma, indicating it is in a pre-commercial, business development phase without a dedicated sales force or integrated deployment.

  • Regulatory and commercial scale. Incumbents like Abbott have decades of experience navigating FDA pathways and global reimbursement systems for diagnostics.
  • Consumer traction and data network effects. Companies like Levels have already scaled to a user base that generates continuous, real-world metabolic data, creating a potential data advantage.
  • Clinical validation and trust. New diagnostic paradigms require extensive published studies to gain adoption; Math Biology has not yet publicized peer-reviewed clinical trial results.

The most plausible 18-month competitive scenario hinges on partnership execution and early validation data. If Math Biology successfully leverages its Innovit accelerator connection to secure a pilot with a pharmaceutical company for treatment monitoring, it could carve out a sustainable niche as a specialized service provider. The "winner" in this case would be a nimble, asset-light research partner like SOPHiA GENETICS, which has built a business on pharma collaborations. Conversely, if consumer metabolic health platforms continue to lower costs and integrate more biomarkers, they could make the case for population-scale screening, rendering a point-in-time, clinic-based assessment less compelling. The "loser" would then be any capital-intensive, hardware-dependent startup, like Math Biology, that fails to achieve commercial density before software-based alternatives mature.

Data Accuracy: YELLOW -- Competitive analysis is based on inferred market segments and public company profiles; no direct competitive claims from the subject are cited.

Opportunity

PUBLIC The potential prize for Math Biology is a foundational shift in metabolic health monitoring, moving diagnosis from invasive, symptom-driven tests to a continuous, predictive digital twin system.

The headline opportunity is to become the standard-of-care infrastructure for non-invasive metabolic screening in clinical and research settings. The company's core thesis, that bioelectrical signals from 61 body points can be processed by proprietary AI to create a digital twin of metabolism, targets a fundamental inefficiency in healthcare: the inability to see metabolic dysfunction before it manifests as disease [Perplexity Sonar Pro Brief, current]. The cited patent for the DMA® biosensor, granted in April 2023, provides a tangible, defensible starting point for this platform [Perplexity Sonar Pro Brief, current]. If the technology is validated, it could position the company not as a single diagnostic tool but as the underlying data layer for a new class of preventative and personalized medicine applications.

Growth Scenarios

Three concrete paths to scale are visible from the company's stated target customers and early signals.

Scenario What happens Catalyst Why it's plausible
Research & Pharma Partnership DMA® becomes the preferred tool for longitudinal metabolic monitoring in clinical trials, providing dense biomarker data for drug efficacy. A formal partnership with a pharmaceutical company for a specific therapeutic area trial. The company explicitly lists pharmaceutical companies as target customers and is exhibiting at BIO International Convention 2026, a major biopharma partnering event [Perplexity Sonar Pro Brief, current] [BIO International Convention].
Clinic & Insurance Adoption The technology is adopted by specialized clinics (e.g., for chronic disease management) and integrated into insurance providers' preventative care programs. A pilot deployment with a named clinic network or insurer demonstrating cost savings from early intervention. The company's focus on non-invasive, real-time monitoring for chronic conditions aligns with payer and provider incentives to reduce long-term costs [Perplexity Sonar Pro Brief, current]. Selection for the Innovit acceleration program provides a link to potential pilot partners [Math Biology, May 2024].

What compounding looks like is a classic data network effect in a specialized domain. Each new patient scan adds to the proprietary dataset of bioelectrical signals correlated with metabolic states. This dataset, which the company claims already encompasses 7,000 biomarkers, would be used to refine the AI algorithms that power the digital twin, improving accuracy and predictive power [Perplexity Sonar Pro Brief, current]. In turn, more accurate predictions would drive higher clinical utility and adoption, attracting more scans and further enriching the dataset. This creates a significant data moat; replicating the depth and specificity of this longitudinal metabolic map would require equivalent time and patient access, not just similar technology.

The size of the win can be framed by looking at comparable companies that have built valuable businesses on proprietary health data platforms. For example, Tempus Labs, which builds clinical and molecular data platforms for oncology, reached a reported valuation of over $8 billion in its 2022 funding round [Bloomberg, 2022]. While Math Biology is earlier and focused on a different modality (bioelectrical signals vs. genomics), the comparable illustrates the value of becoming an essential data infrastructure layer in a high-stakes therapeutic area. If the Research & Pharma Partnership scenario plays out and DMA® gains traction in metabolic disorder trials, the company could position itself for a strategic acquisition or a standalone path at a significant premium to its current, undisclosed valuation (scenario, not a forecast).

Data Accuracy: YELLOW -- Scenarios are extrapolated from company statements and event participation; comparable valuation is from a public peer.

Sources

PUBLIC

  1. [Perplexity Sonar Pro Brief, current] Math Biology srl company and product description | https://mathbiology.tech/about-us/

  2. [SignalBase] Revolutionizing Healthcare: Math Biology Secures $1.5 Million in Funding for Breakthrough Health Technology | https://www.trysignalbase.com/news/funding/revolutionizing-healthcare-math-biology-secures-1.5-million-in-funding-for-breakthrough-health-technology

  3. [Math Biology, May 2024] About Us - Math Biology | https://mathbiology.tech/about-us/

  4. [BIO International Convention] Math Biology srl - BIO International Convention 2025 | https://convention.bio.org/exhibitors/math-biology-srl

  5. [Grand View Research] Digital Twin in Healthcare Market Size Report, 2023-2030 | https://www.grandviewresearch.com/industry-analysis/digital-twin-healthcare-market-report

  6. [Bloomberg, 2022] Tempus Labs Valuation | https://www.bloomberg.com/news/articles/2022-04-12/tempus-labs-raises-200-million-at-8-1-billion-valuation

Articles about Math Biology srl

View on Startuply.vc